Omega Therapeutics, Inc. announced that it has received $126 million in funding from a group of investors

On March 30, 2021, Omega Therapeutics, Inc. closed the transaction. The company has issued 42,000,000 series C preferred shares for the gross proceeds of $126,000,000 in the transaction. The transaction included participation from The Invus Group, LLC, Fidelity Management & Research Company LLC a fund managed by BlackRock, Inc., CHI Advisors LLC, Point72 Asset Management, L.P., Mirae Asset Capital Co., Ltd, Logos Global Management, L.P., existing investor Flagship Pioneering, and other new and existing investors.

The company raised $210,000,000 in funding till date.